High Density Lipoproteins and Diabetes

Epidemiological studies have established that a high plasma high density lipoprotein cholesterol (HDL-C) level is associated with reduced cardiovascular risk. However, recent randomised clinical trials of interventions that increase HDL-C levels have failed to establish a causal basis for this relationship. This has led to a shift in HDL research efforts towards developing strategies that improve the cardioprotective functions of HDLs, rather than simply increasing HDL-C levels. These efforts are also leading to the discovery of novel HDL functions that are unrelated to cardiovascular disease. One of the most recently identified functions of HDLs is their potent antidiabetic properties. The antidiabetic functions of HDLs, and recent key advances in this area are the subject of this review. Given that all forms of diabetes are increasing at an alarming rate globally, there is a clear unmet need to identify and develop new approaches that will complement existing therapies and reduce disease progression as well as reverse established disease. Exploration of a potential role for HDLs and their constituent lipids and apolipoproteins in this area is clearly warranted. This review highlights focus areas that have yet to be investigated and potential strategies for exploiting the antidiabetic functions of HDLs.

Automated summary

Epidemiological studies have shown a link between high plasma high density lipoprotein cholesterol (HDL-C) levels and reduced cardiovascular risk, but recent clinical trials of interventions to increase HDL-C levels have not established a causal basis for this relationship. This has shifted research towards enhancing the cardioprotective functions of HDLs, with a focus on discovering novel functions like the antidiabetic properties of HDLs. There is a growing need to explore the potential role of HDLs in diabetes and develop new approaches to complement existing therapies.